SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-041486
Filing Date
2023-02-17
Accepted
2023-02-17 06:31:54
Documents
13
Period of Report
2023-02-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d447068d8k.htm   iXBRL 8-K 32122
2 EX-3.1 d447068dex31.htm EX-3.1 127601
  Complete submission text file 0001193125-23-041486.txt   315021

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA verv-20230214.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20230214_lab.xml EX-101.LAB 19483
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20230214_pre.xml EX-101.PRE 12154
7 EXTRACTED XBRL INSTANCE DOCUMENT d447068d8k_htm.xml XML 3676
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 23640230
SIC: 2834 Pharmaceutical Preparations